Key result
Concomitant use of proton pump inhibitors did not significantly modify the protective effect of clopidogrel against MACE after coronary stent implantation (interaction HR 1.20; 95% CI 0.91-1.58).
Why the study?
Does concomitant use of proton pump inhibitors modify the protective effect of clopidogrel on major adverse cardiovascular events in patients following coronary stent implantation?
Cohort (n=13,001)
Does concomitant use of proton pump inhibitors modify the protective effect of clopidogrel on major adverse cardiovascular events in patients following coronary stent implantation?
Hazard Ratio: 1.2 (95% CI 0.91–1.58)
The use of proton pump inhibitors does not significantly modify the protective effect of clopidogrel against major adverse cardiovascular events following coronary stent implantation.
No takes yet. Share an insight, caveat, or question.
Reassures on PPI safety with clopidogrel post-stent; leaves open confirmation in randomized trials.
Schmidt et al. (2011) conducted a cohort in coronary stent implantation (n=13,001). Concomitant use of clopidogrel and proton pump inhibitors vs. Non-use of proton pump inhibitors was evaluated on Major adverse cardiovascular events (MACE) (HR 1.20, 95% CI 0.91-1.58). Concomitant use of proton pump inhibitors did not significantly modify the protective effect of clopidogrel against MACE after coronary stent implantation (interaction HR 1.20; 95% CI 0.91-1.58).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: